pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Apr 24·3 min read
save

STAT+: Utah medical board calls for immediate suspension of state’s AI doctor experiment

A Utah pilot to renew prescriptions using a bot faced backlash from the state's medical board, which called for an immediate suspension.

Apr 24, 2026·read at STAT ↗

STAT PlusHealth tech Utah medical board calls for immediate suspension of state’s AI doctor experiment The state’s pilot puts Utah residents at risk, the board wrote Manage alerts for this article Email this article Share this article By Mario AguilarApril 24, 2026 Health Tech Correspondent Mario Aguilar[email protected]Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the practice of health care and the business and policy challenges to realizing tech’s promise. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter.

You can reach Mario on Signal at mariojoze.13. Utah’s high-profile experiment with using an artificial intelligence system to renew prescriptions without physician oversight is facing its first major challenge as doctors in the state push back. Utah’s Office of Artificial Intelligence Policy in January announced an agreement with AI doctor startup Doctronic to launch a chatbot that can conduct a clinical evaluation of a patient and autonomously renew prescriptions for nearly 200 drugs.

In a letter published Friday, the Utah Medical Licensing Board said it only learned about the agreement after the plan had been launched and asked the state to halt the program.Advertisement “Proceeding with this agreement without consulting the Medical Board potentially places Utah citizens at risk and remains a major concern of the board,” they wrote. “It is the strong recommendation of the Utah Medical Licensing Board that this program be immediately suspended pending further discussion.” STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%!

2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In Artificial intelligence, health tech, Policy Submit a correction requestReprints Mario Aguilar Health Tech Correspondent Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the practice of health care and the business and policy challenges to realizing tech’s promise.

He’s also the co-author of the free, twice weekly STAT Health Tech newsletter. You can reach Mario on Signal at mariojoze.13. Newsletter Tech is transforming health care and life sciences.

Our original reporting is here to keep you ahead of the curve. Recommended Health April 25, 2026 Nancy Cox, a CDC veteran and a stalwart in global flu research, dies at 77 First Opinion Podcast April 25, 2026 The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs Advertisement Biotech April 24, 2026 STAT Plus: FDA to speed up review of three psychedelics as mental health treatments The Readout LOUD April 24, 2026 STAT Plus: A biotech VC on what Eli Lilly saw in a struggling cancer startup for $3.2B Pharmalot April 24, 2026 STAT Plus: Up and down the ladder: The latest comings and goings Subscriber Picks

source

Reporting by STAT.

read at STAT ↗
568 words · retrieved Apr 26
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Wearable Devices Ltd.2Wearable Devices Ltd.2
drugs
Edluar
topics
OncologyPsychiatry & CNS

related stories

  • Apr 25Nancy Cox, a CDC veteran and a stalwart in global flu research, dies at 77STAT
  • Apr 24Growing use of guest editors has turned some journals into a ‘playground of bad science’STAT
  • May 6Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myelomaonclive
  • May 6Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Canceronclive
  • May 6Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphomaonclive